A genetic snapshot of small cell lung cancer

Cancer Discovery

Volumn 2, Issue 9, 2012, Pages 769-771

  Rosell, Rafael ^a,b   Wannesson, Luciano ^c  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b INSTITUT UNIVERSITARI DEXEUS   (Spain)

^c ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS SIGNAL REGULATING KINASE 1; BRCA1 PROTEIN; CARBOPLATIN; CISPLATIN; CYCLINE; DNA DEPENDENT PROTEIN KINASE; ETOPOSIDE; HISTONE H2AX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; OLAPARIB; PACLITAXEL; PROTEIN BCL 2; PROTEIN P130; PROTEIN P53; PROTEIN TYROSINE KINASE; RAD51 PROTEIN; RETINOBLASTOMA PROTEIN; THYMIDYLATE SYNTHASE; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR EZH2;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CHEMOSENSITIVITY; DNA REPAIR; DOWN REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; HOMOLOGOUS RECOMBINATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; WESTERN BLOTTING;

HUMANS; LUNG NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; PROTEOMICS; SMALL CELL LUNG CARCINOMA;

EID: 84866343458     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-12-0346     Document Type: Article

References (13)

1. van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet 2011; 378: 1741-55.
2. Schaffer BE, Park KS, Yiu G, Conklin JF, Lin C, Burkhart DL, et al. Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. Cancer Res 2010; 70: 3877-83.
3. Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2012;2:798-811.
4. Hegan DC, Lu Y, Stachelek GC, Crosby ME, Bindra RS, Glazer P M. Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc Natl Acad Sci U S A 2010; 107: 2201-6.
5. Rosell R. Triple-negative breast cancer. In: Rosell R, editor. Molecularbased decision making for personalized cancer management. London (UK): Future Medicine; 2012.
6. Chan N, Koritzinsky M, Zhao H, Bindra R, Glazer PM, Powell S, et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res 2008; 68: 605-14.
7. Fennell DA, Rudd RM. Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development. Lancet Oncol 2004; 5: 354-62.
8. Deeb KK, Michalowska AM, Yoon CY, Krummey SM, Hoenerhoff MJ, Kavanaugh C, et al. Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis. Cancer Res 2007; 67: 8065-80.
9. Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T, et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med 2010; 16: 286-94.
10. Gonzalez ME, DuPrie ML, Krueger H, Merajver SD, Ventura AC, Toy KA, et al. Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer. Cancer Res 2011; 71: 2360-70.
11. Santarpia M, Magri I, Sanchez-Ronco M, Costa C, Molina-Vila MA, Gimenez-Capitan A, et al. mRNA expression levels and genetic status of genes involved in the EGFR and NF-kappaB pathways in metastatic non-small-cell lung cancer patients. J Transl Med 2011; 9: 163.
12. Fujii S, Tokita K, Wada N, Ito K, Yamauchi C, Ito Y, et al. MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes. Oncogene 2011; 30: 4118-28.
13. Zhang B, Liu XX, He JR, Zhou CX, Guo M, He M, et al. Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. Carcinogenesis 2011; 32: 2-9.